The Royal Marsden NHS Foundation Trust
London, United Kingdom
52 recruiting
Showing 1–20 of 61 trials
Recruiting
Phase 2
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
Nurix Therapeutics, Inc.100 enrolled30 locationsNCT07221500
Recruiting
Phase 1
NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
Locally Advanced Rectal Cancer (LARC)
Akamis Bio30 enrolled7 locationsNCT06459869
Recruiting
Phase 1Phase 2
DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr
Bladder Cancer
University College, London52 enrolled7 locationsNCT04106115
Recruiting
Phase 3
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
Melanoma, Cutaneous Malignant
Immatics US, Inc.360 enrolled66 locationsNCT06743126
Recruiting
Phase 3
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Non-small Cell Lung CancerAdvanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc.480 enrolled74 locationsNCT07185997
Recruiting
Phase 1
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Follicular LymphomaLymphoma Diffuse Large B-cellLymphoma, Non-Hodgkin's
Eli Lilly and Company460 enrolled46 locationsNCT07226843
Recruiting
Phase 3
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb850 enrolled255 locationsNCT07361497
Recruiting
Phase 3
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb750 enrolled273 locationsNCT07361510
Recruiting
Phase 3
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Colorectal Neoplasms
Seagen, a wholly owned subsidiary of Pfizer400 enrolled381 locationsNCT05253651
Recruiting
Phase 3
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Non-small Cell Lung CancerAnaplastic Lymphoma Kinase-positive
Nuvalent Inc.450 enrolled155 locationsNCT06765109
Recruiting
Phase 1
A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
Ovarian CancerHead and Neck CancerSynovial Sarcomas+1 more
Zelluna Immunotherapy AS9 enrolled2 locationsNCT07613723
Recruiting
Phase 1
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Ewing SarcomaColorectal Adenocarcinoma
Inhibrx Biosciences, Inc411 enrolled36 locationsNCT03715933
Recruiting
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Prostate Cancer
Prostate Cancer Clinical Trials Consortium5,000 enrolled121 locationsNCT03151629
Recruiting
Phase 3
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Advanced Melanoma
Replimune, Inc.400 enrolled81 locationsNCT06264180
Recruiting
Phase 1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast Neoplasms+9 more
Seagen, a wholly owned subsidiary of Pfizer1,006 enrolled159 locationsNCT04389632
Recruiting
Phase 1Phase 2
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Endometrial CancerRecurrent Ovarian CancerLow Grade Serous Ovarian Cancer+3 more
Regeneron Pharmaceuticals890 enrolled52 locationsNCT03564340
Recruiting
Phase 3
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
Relapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
Regeneron Pharmaceuticals470 enrolled169 locationsNCT06149286
Recruiting
Phase 4
Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
Desmoid TumorAggressive Fibromatosis
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany50 enrolled21 locationsNCT07176689
Recruiting
Phase 2
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Metastatic Breast CancerBreast NeoplasmsGastroesophageal Junction Adenocarcinoma+7 more
Seagen, a wholly owned subsidiary of Pfizer172 enrolled141 locationsNCT06157892
Recruiting
Phase 2
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
Refractory Follicular LymphomaRelapsed Follicular Lymphoma
University of Birmingham284 enrolled25 locationsNCT05848765